Cornea

This NDA transfer marks the fourth FDA-approved ophthalmic product purchased by Harrow earlier in 2023 now commercially available in the US.

With the potential to impact millions of patients, a study finds that biomimetic materials pulsed with low-energy blue light can reshape damaged corneas, including thickening the tissue.

Cedars-Sinai research is the first to uncover disease-related changes to the cornea and to propose potential therapeutic approaches to correct diabetic wound healing.

A recent study demonstrates the safety and efficacy of treating eyes with cross-linking after keratoconus relapses following keratoplasty.

A recent study demonstrates the safety and efficacy of treating eyes with cross-linking after keratoconus relapses following keratoplasty.

The use of topical insulin eye drops led to a successful resolution of PEDs in 9 of 11 cases in the study.

Severe ocular surface and corneal damage an unseen public health burden.

Surgeon discusses latest trends for treating cornea.

William B. Trattler, MD, highlights some of the novel therapies for dry eye that have recently been approved by the FDA, along with various treatment approaches that are in development.

Keratopigmentation technique offers therapeutic and cosmetic applications.

Jorge L. Alió, MD, PhD, FEBOphth, shared his pearls situations in which a patient presents with a cataract and corneal opacity at the European Society of Ophthalmology Conference, Prague.

Scientists hope to develop novel AI solutions for the prediction of DPN using corneal OCT images.

The company completed enrollment in less than 6 months from the trial commencement. The phase 3 trial results combined with the completion of the first phase 3 trial are expected to support the company’s targeted NDA submission for Epioxa by the end of 2024.

Dr Zeba A. Syed emphasises the importance of performing surgery sooner rather than later for patients with Pseudomonas scleritis

Ground-breaking treatment for bullous keratopathy approved in Japan

The move could result in changes to guidelines that currently prohibit cornea donations from gay or bisexual men who have had sex with another man in the last 5 years of their life. There's no indication as to whether other queer communities, such as transgender women or nonbinary donors, will be impacted.

According to Bausch + Lomb and Novaliq, MIEBO is the first prescription eye drop approved for dry eye disease that directly targets tear evaporation, based on consistent results from a pair of pivotal Phase 3 trials.

Groundbreaking treatment for patients with bullous keratopathy approved in Japan.

Brian Shafer, MD, discussed Fortisite and the ability to treat corneal ulcers at the 2023 ASCRS annual meeting in San Diego.

Zeba Syed, MD, from Wills Eye Hospital discussed their research on corneal swelling and dynamics during corneal collagen crosslinking at the 2023 ASCRS annual meeting in San Diego.

At the American Society of Cataract and Refractive Surgery annual meeting in San Diego, data was presented from the STORM study that demonstrate vision quality to be a major driver of the patient decision to undergo surgery.

The announcement represents the first FDA-approved, fixed-combination of tropicamide and phenylephrine for mydriasis, according to the company.

Ophthalmology Times© spoke with Greg Kunst about Aurion BioTech's 12-month data from their recent Escalón trial 2023 at the ASCRS annual meeting in San Diego.

In a presentation at the American Society for Cataract and Refractive Surgery annual meeting in San Diego, Ana Balbuena-Pareja, MSc, explained how cenegermin-bkbj ophthalmic solution 0.002% (Oxervate, Dompé) had a positive effect on corneal nerve regeneration and sensation in patients with neurotrophic keratitis.

Physician outlines latest emerging technologies to treat condition